Physician profile
Amberlea Dawn Bradford Elliott
NPI 1801382775
$1,821.82
in general payments reported to CMS, 2019-2025
24 companies · $425 in 2025
The $425 reported for 2025 was more than what a typical Neuroscience (Clinical Nurse Specialist) provider received nationally (typical 2025 total: $136).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $71.58 · 2022: $167 · 2023: $657 · 2024: $501 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,583.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $344.13 | 2023-2025 | |
| Merz Pharmaceuticals, LLC | $214.23 | 2023-2025 | Xeomin |
| Alexion Pharmaceuticals, INC. | $164.75 | 2022-2024 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $140.01 | 2023-2025 | Ajovy, Austedo Xr |
| Ucb, INC. | $136.66 | 2023-2025 | Nayzilam, Briviact, Rystiggo |
| Sk Life Science, INC. | $135.49 | 2023-2025 | Xcopri |
| Celgene Corporation | $105.23 | 2025 | Zeposia |
| Csl Behring | $65.00 | 2022-2024 | Hizentra |
| Argenx US, INC. | $61.28 | 2023-2024 | Vyvgart, Vyvgart Hytrulo |
| Genentech USA, INC. | $58.09 | 2021-2023 | Ocrevus |
| Catalyst Pharmaceuticals, INC. | $55.67 | 2023 | Firdapse, Fycompa |
| Medtronic, INC. | $48.72 | 2021 | |
| Impel Pharmaceuticals INC. | $47.04 | 2022-2023 | Trudhesa |
| Corium, LLC | $39.36 | 2023 | Adlarity |
| Neurocrine Biosciences, INC. | $29.37 | 2022-2023 | Ingrezza, Ongentys |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $26.46 | 2025 | |
| Acorda Therapeutics, INC | $23.32 | 2023 | Ampyra, Inbrija |
| Janssen Pharmaceuticals, INC | $22.88 | 2022 | |
| Lilly USA, LLC | $21.45 | 2024 | Amyvid |
| Avion Pharmaceuticals | $19.61 | 2023 | Dhivy |
| Azurity Pharmaceuticals, INC. | $17.46 | 2023 | Horizant |
| Eisai INC. | $15.59 | 2024 | |
| Lundbeck LLC | $15.09 | 2024 | Vyepti |
| E.R. Squibb & Sons, L.L.C. | $14.93 | 2023 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amberlea Bradford Elliott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.